In 1Q17, the FDA accepted for review AstraZeneca’s application seeking approval for the Bydureon auto-injector as a treatment option for type-2 diabetes patients. If approved, it would be more convenient to use Bydureon, an important factor in the management of chronic ailments.
Bydureon could play a major role in enabling AstraZeneca (AZN) to compete effectively with other type-2 diabetes players such as Johnson & Johnson (JNJ), Eli Lilly & Co. (LLY), and Merck & Co. (MRK).
Following positive top-line safety results declared in May 2017, AstraZeneca anticipates encouraging results from the Exenatide Study of Cardiovascular Event Lowering (or EXSCEL) outcomes trial, evaluating the efficacy of Bydureon, in 2H17.
The trial has enrolled more than 14,000 type-2 diabetes patients in 35 countries. The results are scheduled to be released earlier than previously expected due to a faster rate of cardiovascular events in patients.
If there are positive clinical results from the EXSCEL trial, Bydureon may witness a robust increase in demand, which could lead to a rise in AstraZeneca’s stock price. This trend could boost the Vanguard Total World Stock ETF (VT), as AstraZeneca makes up about 0.10% of VT’s total portfolio holdings.
In the next article, we’ll discuss the growth prospects for AstraZeneca’s Brilinta.
View more information: https://marketrealist.com/2017/07/bydureon-auto-injector-may-boost-drugs-sales-future-years/